Importantly, NORAD can promote the progression of hepatocellular carcinoma [39], colorectal cancer [40], non-small cell lung cancer [41, 42], and malignant melanoma [43] by targeting different miRNAs. This evidence concerns the gene NORAD and non-small cell lung carcinoma.